Introduction DMD #37360
were initiated by the addition of NADPH (1 mM final); an equivalent volume of water was added to the control. After 0, 2, 5, 10, 15, and 40 min, the reactions were quenched by the addition of 10 µL of acetonitrile and samples were placed on ice. For heme adduct analysis, incubation mixtures were injected onto a PROTO 300, C 4 , 5 μm, 2.1 x 250 mm column connected to a Waters Alliance e2695 HPLC system and the mobile phase was a gradient elution with initial conditions of 70% A (0.1% TFA in H 2 O): 30% B (0.05% TFA in ACN) that was ramped linearly to 20% A over 30 min, and then returned to the initial conditions. Heme was monitored using a Waters model 2487 dual wavelength UV/Vis detector at 405 nm. Heme were pre-incubated in a 37 °C shaking water bath. After five minutes the primary reactions were initiated with the addition of NADPH (1 mM, final) and incubated at 37 °C. To allow the inactivation to go to completion (Silverman, 1988) , inactivation essays were incubated for 60 minutes. Then, aliquots of 10 μ L were removed and added to secondary reaction mixtures containing 100 μ M bufuralol and 1 mM NADPH in 100 mM potassium phosphate buffer, pH 7.4, in a final volume of 200 μ L. The secondary mixtures (in triplicate) were incubated for 10 min at 37 °C and quenched with 15 μ L 70% perchloric acid. Reaction mixtures were centrifuged (2000 x g, 5 min) to remove the precipitated enzyme and aliquots of the recovered supernatants were directly injected onto HPLC for analysis as described above.
Spectral Analysis. P450 reduced CO difference spectra were measured using the methods of Omura and Sato (Omura and Sato, 1964) . Primary reactions containing 1 µM recombinant purified CYP2D6, 2 µM recombinant purified P450 NADPH-reductase, 30 µM freshly sonicated L-α-dilauroyl-phosphatidylcholine phospholipids, 100 mM potassium phosphate buffer, pH 7.4, 400 units/mL catalase (8 µg/mL), 80 units/mL superoxide dismutase (0.18 µM), and 16 µM SCH 66712 were incubated for 0-25 minutes with NADPH-generating system. Incubations were terminated by the addition of with ice-cold quenching buffer [100 mM potassium phosphate buffer (pH 7.4) containing 1.0 mM EDTA, 20% glycerol (v/v), 0.50% sodium cholate (w/v), and 0.40% Emulgen 913 (w/v)]. Incubations without SCH 66712 or without NADPH generating system were carried out as controls. Quenched samples were divided into two cuvettes and a baseline spectrum from 400 to 500 nm was recorded using a Cary-300 dual-beam spectrophotometer (Varian, Walnut Creek, CA). To the sample cuvette only, CO was bubbled for 1 min and then ~1-2 mg of Na 2 S 2 O 4 was added to both the reference and sample cuvettes. The spectrum between 400 and 500 nm was recorded. The change in absorbance at 450 nm relative to that at 475 nm was used to determine the P450 content using 91 mM -1 cm -1 as the molar absorptivity (Omura and Sato, 1964) . used. After an initial 20 min hold at 90% A, a linear gradient of 90% A to 5% A over 35 min was applied for resolving of protein components followed by a 10 min hold at 5% A. The column effluent starting at 20 min was directed into an LXQ mass analyzer (Thermo Fischer Scientific, Waltham, MA) operated in the positive ion mode and using the Xcalibur software package. The system had been optimized with horse heart myoglobin. The ESI conditions were sheath gas, 20 arbitrary units; auxiliary gas, 9 arbitrary units; spray voltage, 5 kV; capillary temperature, 275
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°C; capillary voltage, 48 V; and tube lens offset, 120 V. The molecular masses of CYP2D6 were determined by deconvolution of the apoprotein charge envelopes using ProMass software (Novatia, LLC, Mammouth Junction, NJ).
Covalent Binding of SCH 66712 to CYP2D6. For SDS-PAGE analysis, CYP2D6
Supersomes (100 pmol/mL), control and inactivated samples, in the presence of 14 C-labeled or were vortexed for 10 s. The protein pellet obtained after centrifugation at 1800 xg for 10 min was washed a total of 4 times or until the count was less than 300 cpm/0.5 mL for the supernatant. The final protein pellet was dissolved in 0.6 mL of 1 N NaOH, and 0.1 mL of the resulting sample was analyzed using a Beckman LS 6000 scintillation counter.
Metabolism of SCH 66712.
A mixture of CYP2D6 Supersomes (500 pmol), 100 mM potassium phosphate buffer (pH 7.4), SCH 66712 (100 μM), freshly prepared glutathione (10 mM) or freshly prepared N-acetyl cysteine (10 mM) was preincubated for 3 min at 37 °C before addition of 150 μL of the NADPH generating system. The total reaction volume was 1 mL.
After 40 min of incubation in a water bath, all samples were placed on ice and quenched with 60 μL of 1% TFA. All samples were then applied to a 1 mL C 18 solid phase extraction column (Agilent Technologies, Santa Clara, CA) preconditioned by washing with 1 mL of methanol followed by 1 mL of water. After the sample was loaded, the column was washed with 1 mL of water then 2 mL of methanol, and 300 μL of acetonitrile. All fractions were collected. The methanol and acetonitrile fractions were combined and dried under a stream of nitrogen to a final volume of approximately 50 μL. The sample was then resuspended in 200 µL solvent A that was composed of 90% water, 10% methanol, and 0.05% TFA for LC-MS analysis. A 20 µL aliquot of the sample was injected onto a Kinetex C 18 (2.6 μm, 2.1 x 100 mm) column (Phenomenex, Torrance, CA) for chromatographic separation using an Alliance 2690 HPLC system (Waters, Milford, MA) with a solvent system composed of solvent mixtures A (90% water, 10% methanol, and 0.05% TFA) and B (90% acetonitrile, 10% methanol and 0.05% TFA). After 5 min at the initial conditions (5% B), separation of metabolites was achieved by a linear gradient of 5% B to 50% B over 20 minutes then holding at 50% B for 1 min before returning to the initial conditions. The flow rate was 0.1 mL/min. The column was allowed to reThis article has not been copyedited and formatted. The final version may differ from this version. mass spectrometer with an ESI source in a positive ion mode. The ESI conditions were sheath gas set at 27 arbitrary units, the auxiliary gas was set at 5 arbitrary units, the spray voltage was set at 5 kV, and the capillary temperature was set at 250 °C. (partition ratio +1) was estimated from the intercept of the linear regression line obtained from the lower ratios of SCH 66712 to CYP2D6 with the straight line derived from the higher ratios of SCH 66712 to 2D6 as described previously (Silverman, 1988) . With this method, the turnover number was 4, and consequently the partition ratio was 3 ( Figure 5 ). 
Molecular Modeling and Docking

Covalent
Stoichiometry of Binding.
The stoichiometry of binding of SCH 66712 to CYP2D6 was determined using scintillation counting and 14 C-radiolabeled SCH 66712. Inactivation reactions were treated with 5% sulfuric acid in methanol and protein precipitated as described in the Materials and Methods and as previously described (Chan et al, 1993) . While there was some non-NADPH-dependent binding apparent in samples, the difference between samples that received NADPH and those that did not was ~1.2 nmol SCH 66712 bound/nmol CP2D6 (Table DMD #37360 produced metabolites of SCH 66712 that are more commonly mono-oxygenated on the piperazine or fluorinated heterocyclic aromatic ring end of the molecule (Figure 8 ) consistent with the molecular simulation models. ). The use of radiolabeled SCH 66712 in the inactivation assays allowed for the detection of radiolabeled CYP2D6 using SDS-PAGE with audioradiography and Western blotting supporting adduct formation ( Figure 6 ). Using radiochemical analysis and scintillation counting, the stoichiometry of binding was determined to be ~1.2 further supporting protein adduction (Table   I ).
Discussion
This article has not been copyedited and formatted. The final version may differ from this version. are consistent with the hypothesis that face-to-face and edge-to-edge interactions could be preliminary steps in mechanism-based inhibition.
Since SCH 66712 was first reported as a mechanism-based inhibitor of CYP2D6, a few other compounds have been reported to be mechanism-based inhibitors including a related compound, EMTPP, that was intentionally studied based on its similarity to SCH 66712 (Hutzler et al., 2004) . For EMTPP, the methylene carbon of the ethyl substituent on the imidazole group is the site of oxidation (structure of EMTPP in Supplemental Figure 8 In conclusion, the inactivation of CYP2D6 by SCH 66712 is very potent with production of few metabolites. SCH 66712 causes inactivation likely by apoprotein adduction that we postulate would be at Thr309 based on modeling studies. Finally, the current study supports the notion that some substituted imidazole groups may tend to give rise to inactivation of CYP2D6 and should be examined for mechanism-based inactivation early in the drug discovery process.
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